IL17A and psoriasis: TNFα inhibitors, IL-17 inhibitors, and IL-23 inhibitors have been introduced to treat psoriasis (70), and IL23 inhibitors (IL-1 and IL-36 inhibitors in clinical trials) to treat PPP (58, 71).